Merck Re-enters Flu Vaccine Business: Seals Six-year Afluria Marketing Deal With Australia's CSL
This article was originally published in PharmAsia News
Executive Summary
Merck took its time coming back into the flu vaccine field, but the expansion of world suppliers of vaccines brought a very well-suited partner to its doorstep
You may also be interested in...
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products